DDrare: Database of Drug Development for Rare Diseases

Noxafil - 40 mg/ml sospensione orale uso orale flacone (vetro) 105 ml 1 flacone (DrugBank: -)

ID	Disease name (Link within this page)	Number of trials
299	Cystic fibrosis	1

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2019-004511-31-IT (EUCTR)	21/10/2020	07/10/2020	Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.	Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection. - cASPerCF	Cystic Fibrosis and Aspergillus infection. MedDRA version: 20.0;Level: LLT;Classification code 10003488;Term: Aspergillosis;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]	Trade Name: NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE Product Name: Noxafil Product Code: [NA] INN or Proposed INN: Posaconazolo Trade Name: Noxafil Product Name: Noxafil Product Code: [NA] INN or Proposed INN: POSACONAZOLO Trade Name: Noxafil Product Name: Noxafil Product Code: [NA] INN or Proposed INN: POSACONAZOLO Product Name: Noxafil Product Code: [na] INN or Proposed INN: POSACONAZOLO Trade Name: NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE Product Name: Noxafil Product Code: [na] INN or Proposed INN: POSACONAZOLO Trade Name: Noxafil Product Name: Noxafil Product Code: [na] INN or Proposed INN: Posaconazolo	IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	135	Phase 2;Phase 3	Portugal;France;Czech Republic;Greece;Spain;Ireland;Netherlands;Germany;United Kingdom;Switzerland;Italy;Sweden

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

EUCTR2019-004511-31-IT
(EUCTR)

21/10/2020

07/10/2020

Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection.

Prospective validation and clinical evaluation of a new posaconazole dosing regimen for children and adolescents with cystic fibrosis and Aspergillus infection. - cASPerCF

Cystic Fibrosis and Aspergillus infection.
MedDRA version: 20.0;Level: LLT;Classification code 10003488;Term: Aspergillosis;System Organ Class: 100000004862;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]

Trade Name: NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE
Product Name: Noxafil
Product Code: [NA]
INN or Proposed INN: Posaconazolo
Trade Name: Noxafil
Product Name: Noxafil
Product Code: [NA]
INN or Proposed INN: POSACONAZOLO
Trade Name: Noxafil
Product Name: Noxafil
Product Code: [NA]
INN or Proposed INN: POSACONAZOLO
Product Name: Noxafil
Product Code: [na]
INN or Proposed INN: POSACONAZOLO
Trade Name: NOXAFIL - 40 MG/ML SOSPENSIONE ORALE USO ORALE FLACONE (VETRO) 105 ML 1 FLACONE
Product Name: Noxafil
Product Code: [na]
INN or Proposed INN: POSACONAZOLO
Trade Name: Noxafil
Product Name: Noxafil
Product Code: [na]
INN or Proposed INN: Posaconazolo

IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

135

Phase 2;Phase 3

Portugal;France;Czech Republic;Greece;Spain;Ireland;Netherlands;Germany;United Kingdom;Switzerland;Italy;Sweden